Pharma Stocks
-
Assessing UroGen Pharma (URGN) Valuation After ZUSDURI Secures Permanent J Code
UroGen Pharma (URGN) shares are in focus after the company reported that its bladder cancer therapy ZUSDURI now has a…
Read More » -
Insufficient Growth At NATCO Pharma Limited (NSE:NATCOPHARM) Hampers Share Price
When close to half the companies in India have price-to-earnings ratios (or “P/E’s”) above 25x, you may consider NATCO Pharma…
Read More » -
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 5.8% in the afternoon session after the company announced it had entered…
Read More » -
Is This Deep-Value Pharma Name Finally Near a Turning Poi
Bristol-Myers Squibb’s share price has been grinding lower, but fresh drug news, oncology milestones and a divided Wall Street are…
Read More » -
Tempus AI (TEM) Stock: Why Big Pharma Is Betting Big on This AI Platform
TLDR Tempus AI total contract value exceeded $1.1 billion, marking highest level in company history Company signed 70 data agreements…
Read More » -
Jenburkt Pharmaceuticals Downgraded to Sell Amid Technica…
Technical Trends Turn Bearish The primary catalyst for the downgrade lies in the technical analysis of Jenburkt Pharmaceuticals’ stock price…
Read More » -
Should NewAmsterdam’s Multi-Indication Obicetrapib Strategy Reshape How NAMS Investors View Pipeline Concentration?
NewAmsterdam Pharma recently outlined its late-stage plans for obicetrapib, including an expected EMA approval decision in the second half of…
Read More » -
Did COACH Trial Combo Data and FDA Priority Review Just Shift Ascendis Pharma’s (ASND) Investment Narrative?
Ascendis Pharma recently reported past Week 52 topline results from its Phase 2 COACH trial, showing that once-weekly TransCon CNP…
Read More » -
Optimistic Investors Push Sumitomo Pharma Co., Ltd. (TSE:4506) Shares Up 26% But Growth Is Lacking
Despite an already strong run, Sumitomo Pharma Co., Ltd. (TSE:4506) shares have been powering on, with a gain of 26%…
Read More » -
Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised the…
Read More »